Gastrointestinal bleeding related to liver cirrhosis Medical Services in China

Gastrointestinal bleeding related to liver cirrhosis—commonly termed variceal hemorrhage—is a life-threatening complication arising from portal hypertension secondary to advanced chronic liver disease. Cirrhosis induces structural distortion and fibrotic scarring of hepatic parenchyma, leading to increased resistance to portal blood flow. This results in elevated portal venous pressure (>10 mmHg), triggering the formation of portosystemic collateral vessels—most critically esophageal and gastric varices. These fragile, dilated submucosal veins lack supportive tissue and are prone to rupture under hemodynamic stress (e.g., transient increases in intra-abdominal or intrathoracic pressure), causing acute, often massive upper GI bleeding. Less commonly, bleeding may originate from portal hypertensive gastropathy or ectopic varices (e.g., duodenal, colonic). Epidemiologically, approximately 5–15% of patients with compensated cirrhosis develop varices annually; among those with established varices, the annual risk of first bleed is 5–15%, rising to 30–40% in those with large varices or red wale signs. Mortality remains high: 15–20% within 6 weeks of an initial episode, with rebleeding occurring in 60% of untreated survivors within 1 year. Key risk factors include Child-Pugh class C or MELD score ≥15, large varices, active alcohol use, coagulopathy (low platelets, prolonged INR), bacterial infection (e.g., spontaneous bacterial peritonitis), and ongoing portal hyperdynamic circulation. Beyond acute mortality, recurrent bleeding profoundly impairs quality of life—patients experience persistent fatigue, anxiety about sudden hemorrhage, dietary restrictions (e.g., avoidance of coarse foods), reduced physical activity, social withdrawal, and significant caregiver burden. Hospitalizations, endoscopic surveillance, and long-term pharmacotherapy (e.g., non-selective beta-blockers) contribute to psychological distress and financial strain. Early diagnosis via screening gastroscopy in newly diagnosed cirrhosis is standard of care; management hinges on multidisciplinary coordination between hepatology, gastroenterology, interventional radiology, and critical care. Without timely intervention—including endoscopic band ligation, pharmacologic vasoconstriction (terlipressin/octreotide), antibiotics, and definitive portal pressure reduction (e.g., TIPS)—outcomes deteriorate rapidly. Patient education on symptom recognition (e.g., hematemesis, melena, syncope), strict adherence to prophylactic therapy, and abstinence from alcohol and NSAIDs are essential components of holistic care.

Gastrointestinal bleeding in patients with liver cirrhosis is most commonly attributable to portal hypertension–induced esophageal or gastric varices, though other contributors—including portal hypertensive gastropathy, gastric antral vascular ectasia (GAVE), and coagulopathy—must be considered. Management requires a multidisciplinary, risk-stratified approach integrating hemodynamic stabilization, endoscopic intervention, pharmacotherapy, and long-term secondary prevention. Prompt recognition and coordinated care are critical, as variceal hemorrhage carries a 20% in-hospital mortality rate and a high risk of rebleeding within six weeks without appropriate prophylaxis.

Conservative treatment forms the initial cornerstone of management and begins with immediate resuscitation. Patients require strict bed rest, continuous cardiorespiratory monitoring, and large-bore intravenous access. Crystalloid infusion is initiated cautiously to avoid volume overload and precipitating hepatic encephalopathy; goal-directed fluid resuscitation targets systolic blood pressure ≥90 mmHg and urine output ≥30 mL/h, while avoiding overtransfusion. Packed red blood cells are transfused only to maintain hemoglobin between 7–9 g/dL (restrictive strategy), as liberal transfusion increases mortality in cirrhotic patients. Fresh frozen plasma, platelets, and vitamin K may be administered selectively based on coagulation profile (INR >2.5) and active bleeding, but routine correction is discouraged unless invasive procedures are planned. Nasogastric aspiration helps assess ongoing upper GI bleeding but is not routinely recommended for diagnosis alone. Airway protection is prioritized in altered-mental-status patients to prevent aspiration pneumonia.

Pharmacologic therapy is integral at all stages. Intravenous octreotide (50 mcg bolus followed by 50 mcg/h continuous infusion) or terlipressin (2 mg IV bolus, then 1–2 mg every 4–6 hours) is initiated immediately upon suspicion of variceal bleeding to reduce portal pressure and splanchnic blood flow. These agents significantly improve hemostasis rates when combined with endoscopy. Antibiotic prophylaxis—typically intravenous ceftriaxone 1 g daily for 7 days—is mandatory to reduce bacterial infections, which occur in up to 40% of admitted patients and independently increase mortality. For secondary prophylaxis, non-selective beta-blockers (NSBBs) such as propranolol (starting at 10–20 mg twice daily, titrated to resting heart rate 55–60 bpm or maximal tolerated dose) or carvedilol (6.25 mg once daily, titrated to 12.5 mg daily) are first-line to lower hepatic venous pressure gradient (HVPG). Endoscopic variceal ligation (EVL) remains the gold-standard primary endoscopic modality for acute variceal hemorrhage and for eradication of medium-to-large esophageal varices. Band ligation is repeated every 2–4 weeks until varices are obliterated, followed by surveillance every 6–12 months. In gastric varices—particularly isolated gastric varices type 2 (IGV2) or gastroesophageal varices (GOV2)—cyanoacrylate injection (e.g., N-butyl-2-cyanoacrylate) is superior to EVL due to higher obliteration rates and lower rebleeding risk.

Surgical and interventional options are reserved for refractory or recurrent bleeding uncontrolled by endoscopic and medical therapy. Transjugular intrahepatic portosystemic shunt (TIPS) is indicated in patients with Child–Pugh class A or B cirrhosis who fail endoscopic and pharmacologic control, or experience early rebleeding (<72 hours post-index bleed). Polytetrafluoroethylene (PTFE)-covered stents have reduced shunt dysfunction and improved 1-year patency (>85%) compared to bare-metal stents. Surgical shunts (e.g., distal splenorenal shunt) are rarely performed today due to high operative morbidity and limited availability of experienced hepatobiliary surgeons. Liver transplantation remains the definitive curative intervention for eligible patients with decompensated cirrhosis and recurrent variceal bleeding; it addresses both the underlying liver disease and portal hypertension. Pre-transplant TIPS may serve as a bridge in select cases.

China offers distinct advantages in the comprehensive management of cirrhosis-related GI bleeding. First, China’s national endoscopy networks—supported by the Chinese Society of Gastroenterology—ensure rapid access to high-volume centers where advanced endoscopic techniques (including cyanoacrylate injection, balloon-occluded retrograde transvenous obliteration [BRTO], and EUS-guided coil+glue injection) are standardized and widely available. Second, cost-effective, domestically manufactured somatostatin analogues and covered TIPS stents have improved affordability and accessibility across tier-2 and tier-3 cities. Third, integrated hepatology–endoscopy–interventional radiology teams operate under unified clinical pathways endorsed by the National Health Commission, minimizing delays in triage and escalation. Fourth, China’s robust real-world data infrastructure enables dynamic risk modeling (e.g., incorporating spleen stiffness measurement via 2D-SWE and platelet count to predict variceal bleeding) that informs personalized prophylaxis strategies. Finally, telemedicine platforms facilitate longitudinal follow-up and medication adherence monitoring in rural populations, reducing late presentation and improving secondary prevention compliance.

Recovery and long-term management emphasize patient education and structured surveillance. Patients must abstain absolutely from alcohol and NSAIDs, and avoid constipation (via fiber supplementation and lactulose if needed) to prevent rises in portal pressure. Dietary counseling should promote adequate protein intake (1.2–1.5 g/kg/day) while monitoring for early signs of hepatic encephalopathy. All patients require lifelong NSBB therapy unless contraindicated (e.g., asthma, bradycardia, hypotension), with regular assessment of HVPG response where feasible. Surveillance endoscopy is recommended every 6–12 months after variceal eradication, or annually in those with persistent small varices. Vaccination against hepatitis A and B is reinforced, and metabolic comorbidities (e.g., diabetes, obesity) are actively managed to mitigate further liver injury. Psychosocial support—including counseling for anxiety related to rebleeding risk—and caregiver training in recognizing prodromal symptoms (melena, hematemesis, dizziness, orthostatic hypotension) are essential components of holistic recovery. With optimized multidisciplinary care, five-year survival following a first variceal bleed exceeds 50% in well-selected patients, underscoring the importance of timely, protocol-driven intervention.